Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

337 results about "Squamous carcinoma" patented technology

Squamous cell carcinoma is an extremely common form of skin cancer which is usually benign, especially if caught early. In almost 97% of cases, the cancer can be excised and the patient will fully recover. ... The first sign of squamous cell carcinoma is usually a reddened, scaly patch on the skin. Sometimes a lump or nodule will develop.

A and C macrocyclic oxidation substituted pentacyclic triterpanoids and preparation method and use thereof

The present invention relates to a pentacyclic triterpanoid derivative of multiple-oxide substitution of the A ring and the C ring and the medicine salt or solvate of the derivative, and the present invention also relates to the preparation method, the drug combination, and medical use of the derivative. The compound of the present invention has the functions of inhibiting the activity of six human tumor cell strains in vitro, such as human prostate cancer cell (PC-3), nasopharyngeal carcinoma cells (CNE), oral squamous carcinoma cell(KB), human lung cancer cell (A549), human hepatoma cell (BEL-7404), and human cervix cancer cell (Hela), and the function of the invention is at the same magnitude of the positive control of cisplatin, thereby the compound can be used as expected antitumor drug. The compound of the present invention also inhibits the alpha glucosidase strongly, and the inhibiting effect is greater than the positive control of acarbose, thereby the compound can be used as expected medicine for preventing and treating diabetes and the treatment of the virus diseases.
Owner:ZHEJIANG HISUN PHARMA CO LTD

Quercetin-3-O-acyl ester and preparation method thereof

The invention relates to quercetin-3-O-acyl ester and a preparation method thereof and belongs to the technical field of pharmaceutical chemistry. The preparation method comprises the following steps: taking cheap rutin as a starting raw material and preparing a quercetin-3-O-acyl ester compound through benzylation, hydrolysis under the acidic conditions, esterification, catalytic hydrogenolysis and other reactions. The method has the characteristics of good selectivity, mild reaction condition, high yield, low cost, simplicity and convenience in operation, easiness in industrial production and the like. In addition, the inhibitory effect of the obtained quercetin-3-O-acyl ester on human esophageal squamous carcinoma cells EC9706, human prostatic cancer cells PC-3 and human gastric cancer cells MGC-803 is remarkably superior to that of quercetin; and the quercetin-3-O-acyl ester can be used in the field of foods and medicines and is possible to develop into a new candidate drug for treating tumor.
Owner:ZHENGZHOU UNIV

Dipeptide boric acid composed of carboxylic acid and alpha-amino acid as well as ester compound thereof, and preparation method and application of dipeptide boric acid and ester compound thereof

The invention belongs to the field of drug synthesis and in particular relates to a series of novel peptide boric acids as well as an ester compound or pharmaceutical salt thereof, and a preparation method and application of the peptide boric acids as well as the ester compound or pharmaceutical salt thereof in pharmacodynamics. A structure of the peptide boric acid and the ester compound or pharmaceutical salt thereof is shown in a formula I (described in the specification). The compound provided by the invention can be used for preparing a proteasome inhibitor and can further be used for treating solid tumours and blood tumours, wherein the solid tumours are selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, gastrointestinal stromal tumor, nasopharynx cancer and leukemia; and the blood tumours are selected from multiple myeloma, mantle cell lymphoma and histiocytic lymphoma.
Owner:JIANGSU CHIA TAI FENGHAI PHARMA

Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas

The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt / Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the proliferation and survival of a subset of HNSCC may depend on the Wnt / Fzd pathway. Therefore, the Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.
Owner:RGT UNIV OF CALIFORNIA

Protein chip for detecting esophageal squamous carcinoma marker and kit box of protein chip

The invention discloses a high-throughput multi-index protein chip for screening esophageal squamous carcinoma specific protein markers, and discloses a kit supporting the use. 55 types of esophageal squamous carcinoma differential proteins in the serum or blood plasma are selected and used as the esophageal squamous carcinoma protein markers and protein contrast prepare the protein chip; and the protein chip comprises a substrate, protein detection indicators and a contrast detection indicator coating, wherein the protein detection indicators are distributed as arrays on the substrate. Detection liquid of a supplementary experiment reagent is filled in the kit. By adopting the protein chip, the protein profiles of three types of people, namely, normal people, people subjected to esophageal squamous cell carcinoma precancerous lesions, and people subjected to the esophageal squamous carcinoma, can be determined; and means are provided for screening the esophageal squamous carcinoma in the early stage, diagnosing in mid stage and late stage, as well as monitoring the state of illness.
Owner:JIANGSU YUANHUA BIO TECH

Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas

The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt / Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the growth and survival of a subset of HNSCC may depend on the Wnt / Fzd pathway. Therefore, The Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.
Owner:RGT UNIV OF CALIFORNIA

Novel target gene for diagnosing and treating tongue squamous carcinoma and application thereof

The invention provides a novel target gene for diagnosing and treating tongue squamous carcinoma and application thereof and particularly relates to application of a KLK14 gene and an expression product thereof to diagnosis and treatment of tongue squamous carcinoma. To research the occurrence and development mechanisms of tongue squamous carcinoma, search for an effective molecular target gene for diagnosing and treating tongue squamous carcinoma, promote early diagnosis, prevention and treatment of the disease and lower the death rate of tongue cancer, firstly, RNA-seq sequencing is utilized to detect differential expression genes of tongue squamous carcinoma, cancer branch and normal oral mucosa; secondly, a Real-time PCR technology is utilized to verify the sequencing result; then, an interference technology is utilized, and expression of the candidate gene KLK14 in tongue squamous carcinoma cells SCC15 is silenced. By means of the novel target gene for diagnosing and treating tongue squamous carcinoma and application thereof, an experimental foundation is laid for clinical application of the KLK14 gene to tongue squamous carcinoma, and a new target gene and theoretical basis are provided for early diagnosis and treatment of tongue squamous carcinoma.
Owner:THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV

Novel anti-tumor application of penicillium enol A1 from penicillium citrinum

The invention relates to novel anti-tumor application of an alkaloid compound penicillium enol A1 from penicillium citrinum. The penicillium citrinum IBPT-5 is collected in the China Center for Type Culture Collection (CCTCC), which is located in Wuhan University and has the collection number of CCTCC NO:M2013713, on December 25, 2013. Experiments prove that the compound has better anti-tumor activity on various tumor cells, and can be used for preparing cell proliferation inhibition medicines or anti-tumor medicines for anti-tumor study, wherein tumor cells comprise human colon cancer cells SW620, human hepatoma cells Huh7, human gastric carcinoma cells BGC-823, human colon cancer cells SW480, human esophageal squamous carcinoma cells KYSE450, human esophageal cancer cells EC9706, human highly metastatic lung carcinoma cells 95-D, human hepatoma cells PLC and human gastric carcinoma cells HGC-27.
Owner:FUZHOU UNIV

Genes highly expressed in tongue squamous carcinoma para-carcinoma tissue and applications of genes

The invention provides genes highly expressed in the tongue squamous carcinoma para-carcinoma tissue and applications of the genes, and in particular relates to the LCE3E gene and the GSDMA gene and applications of expression products of the LCE3E gene and the GSDMA gene in diagnosing tongue squamous carcinoma and preparing biological medicines for treating tongue squamous carcinoma. According to the invention, based on the high-throughput sequencing and in combination with the molecular biology experiment, the screened molecular diagnosis and treatment markers, namely, the LCE3E gene and the GSDMA gene for tongue squamous carcinoma are verified, therefore, an experimental foundation is provided for the clinical applications of the LCE3E gene and the GSDMA gene in tongue squamous carcinoma, and thus a novel target gene is provided for the early diagnosis and treatment of tongue squamous carcinoma.
Owner:BEIJING MEDINTELL BIOMED CO LTD

Culture medium for epithelial cells of esophageal squamous carcinoma, culture method and application thereof

ActiveCN113528444AThere will be no interference with the test resultsShort duration of actionCompound screeningApoptosis detectionMatrigelCell culture media
The invention provides a primary cell culture medium for culturing primary esophageal squamous carcinoma epithelial cells and containing a combination of an MST1 / 2 kinase inhibitor and a ROCK kinase inhibitor, and a culture method using the primary cell culture medium. According to the culture method, the primary cells are cultured on a culture vessel coated with extracellular matrigel by using the primary cell culture medium, so that the primary cells are rapidly proliferated. The cell model obtained by the primary cell culture medium and the primary cell culture method can be used for evaluating and screening curative effects of medicines.
Owner:PRECEDO PHARMA CO LTD

Method for distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma

The present invention is a method distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma. In particular, a 10-gene classifier has been identified which can be used to distinguish between primary squamous cell carcinoma of the lung and metastatic head and neck squamous cell carcinoma. These genes include CXCL13, COL6A2, SFTPB, KRT14, TSPYL5, TMP3, KLK10, MMP1, GAS1, and MYH2. A panel of one or more of these genes, or proteins encoded thereby, can be used for early diagnosis and selection of an appropriate therapeutic treatment.
Owner:WISTAR INST THE A CORP OF PA +1

Oral cavity squamous carcinoma diagnosis reagent, reagent kit and preventing and controlling medicament

The invention belongs to the field of the tumor molecular biological, particularly relating to an oral squamous cell carcinoma diagnostic reagent, kits and medicine. The invention solves the technical problem that the existing medicine and reagent can not early diagnose oral squamous cell carcinoma and can not prevent oral carcinogenesis effectively. The invention oral squamous cell carcinoma diagnostic reagent contains the reagent which can detect expression level of protein RACK1 (activated protein kinase C receptor) and its mRNA content. The oral squamous cell carcinoma kits can be obtained with regular technology. By using the method of screening oral squamous cell carcinoma medicine, the medicine can be screened for preventing oral squamous cell carcinoma medicine, for example: by screen, obtaining effective RACK1 gene and RNA interference molecular, moreover the RNA interference result first reveals the functions of the RNA interference molecular in oral neoplasms apoptosis regulation and oral neoplasms apoptosis treatment, with broad application prospect.
Owner:SICHUAN UNIV

Serum protein marker for early screening and diagnosis of esophageal squamous carcinoma, kit and detection method

The invention discloses a serum protein marker for early screening and diagnosis of esophageal squamous carcinoma, and belongs to the field of biomedical technology. The serum protein marker is any one or a combination of two or more of proteins encoded by P53, GNA11, GNAS, PTEN, ACVR1B, FBXW7, EGFR, PDGFRA, SRSF2, MEN1, DAXX or CASP8 genes. Based on the role played by cancer driving genes in tumorigenesis and development, a human protein chip encoded by 138 cancer driving genes is customized, the human protein chip contains 180 human-derived recombinant proteins for screening out potential markers capable of diagnosing caners or other markers capable of characterizing cancers, early detection serum markers of the esophageal squamous carcinoma are primarily screened out by the protein chip, and then are verified by an ELISA indirect method experiment, a group of joint serum protein markers of esophageal squamous carcinoma for the early screening and diagnosis of the esophageal squamouscarcinoma is screened out at last for assisting the clinical diagnosis of the esophageal squamous carcinoma, so that the serum protein marker has better reference value.
Owner:ZHENGZHOU UNIV

Product for performing assisted prediction on postoperative survival time length of esophageal squamous carcinoma patient

The invention discloses a product for performing assisted prediction on postoperative survival time length of an esophageal squamous carcinoma patient. The product comprises substances for detecting 178 miRNA expression quantity substances comprising hsa-miR-218-5p, hsa-miR-142-3p, hsa-miR-150-5p and hsa-miR-205-5p, and records a carrier with the diagnostic criteria and functional expressions as follows: if 0.94dig is less than dip, the postoperative survival time of the esophageal squamous carcinoma patient to be tested is more than 5 years, and if the 0.94dig is more than or equal to dip, the postoperative survival time of the esophageal squamous carcinoma patient to be tested is less than 5 years. After the result of the postoperative survival time of the esophageal squamous carcinoma patient is predicted by using the product, more accurate and effective treatment is adopted, and the patient condition can be effectively improved. In addition, the medicine which influences the expression quantities of hsa-miR-218-5p, hsa-miR-142-3p, hsa-miR-150-5p and hsa-miR-205-5p can be used for treating the esophageal squamous carcinoma.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI

Preparation method and use of quercetin amide derivative

InactiveCN103214445AStrong proliferation inhibitory effectOrganic active ingredientsOrganic chemistryHuman gastric carcinomaQuercitrin
The invention discloses a preparation method of a quercetin amide derivative and application of the quercetin amide derivative in preparing an antitumor drug. The preparation method of the quercetin amide derivative comprises the following steps of: carrying out benzyl selective protection, a Williamson ether forming reaction, a DCC (Dicyclohexylcarbodiimide) condensation reaction, catalytic hydrogenation and the line by using cheap rutin as the material. The preparation method of the quercetin amide derivative can be used for realizing the orientation and efficient modification of the quercetin, and is gentle in reaction conditions, simple to operate, simple in post-treatment and convenient for industrial production. The obtained quercetin amide derivative obviously has a stronger inbibitional effect to proliferation of a human esophageal squamous carcinoma cell EC (Ethyl Cellulose)109, a human esophageal squamous carcinoma cell EC9706, a human gastric carcinoma cell SGC (Soluble Guanylyl Cyclase) 7901 and a mouse melanoma cell B16-f10 relative to the quercetin, and therefore, the quercetin amide derivative is an anti-tumor candidate compound with great potential.
Owner:ZHENGZHOU UNIV

Molecular marker of esophageal squamous carcinoma

The invention discloses a molecular marker of esophageal squamous carcinoma. According to the molecular marker, a high-throughput sequencing result is analyzed by using a bioinformatics method, the result shows a candidate gene CCKBR of esophageal squamous carcinoma, the CCKBR gene is in low expression in tissue of a patent suffering from esophageal squamous carcinoma, proliferation of esophageal squamous carcinoma cells can be inhibited by increasing the expression level of CCKBR, and the research result shows that the CCKBR gene and expression products of the CCKBR gene are potential therapeutic targets of esophageal squamous carcinoma.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD

Esophageal squamous cell carcinoma autoantibody molecular marker model and application thereof

The invention relates to an esophageal squamous cell carcinoma autoantibody molecular marker model and an application thereof. The molecular model mainly comprises an ALDOA autoantibody, an ENO1 autoantibody, a p53 autoantibody, and an NY-ESO-1 autoantibody, and can be used for preparing a kit for distinguishing esophageal squamous carcinoma patients and healthy medical examiners. The kit for detecting esophageal squamous cell carcinoma patients mainly comprises recombinant ALDOAD protein, recombinant ENO1 protein, recombinant p53 protein, and recombinant NY-ESO-1 protein. According to the esophageal squamous cell carcinoma autoantibody molecular marker model and the application thereof, the ENO1 autoantibody is found to be elevated in serum level in the esophageal squamous carcinoma patients for the first time, and is jointly detected with the ALDOA autoantibody, the p53 autoantibody, and the NY-ESO-1 autoantibody for distinguishing the esophageal squamous cell carcinoma patients andthe healthy medical examiners, and has a better distinguishing effect than a single index detection; and in addition, the detection method adopted by the invention is an enzyme-linked immunosorbent assay indirect method, is simple and convenient to implement, has good sensitivity and specificity, and is a method which is mature and reliable and can be widely used in base layer hospitals.
Owner:汕头市颂美恩生物科技有限公司

Application of 20(S)-ginsenoside Rg3 in preparation of medicines for treating non-small cell lung cancer

The invention relates to medicine application of 20(S)-ginsenoside Rg3, in particular to application of 20(S)-ginsenoside Rg3 in preparation of medicines for treating a non-small cell lung cancer. In the invention, selecting a human non-small cell lung cancer cell strain (A549 lung adenocarcinoma, H460 large cell lung cancer and LTEP-78 lung squamous carcinoma) to be inoculated under the skin of a naked mouse, and observing the influence of the SPG-Rg3 on the non-small cell lung cancer; and carrying out CD34 immunohistochemistry staining and TUNEL immunofluorescence staining on tumor tissues, and observing the influence of the SPG-Rg3 on tumor angiogenesis and apoptosis. The inclusion proves that the 20(S)-ginsenoside Rg3 can remarkably inhibit the growth of the non-small cell lung cancer, has the action mechanism related with the promotion of the tumor apoptosis and the inhibition of the tumor angiogenesis and unobvious cooperation action when being combined with cyclophosphamide for application, and can be used for the clinical chemotherapy of the non-small cell lung cancer.
Owner:北京鑫利恒医药科技发展有限公司

Application of ANO1 protein in prediction on prognosis of esophagus cancer and precancerous lesion risk

The invention belongs to the field of prognosis estimation and canceration risk prediction on clinic of molecular biology, and particularly relates to application of a molecule of a detection ANO1 protein in the preparation of a kit or a detection agent for the prognosis estimation and precancerous disease progression risk prediction of esophageal squamous carcinoma. The molecule expressed by the detection ANO1 protein can be a nucleic acid, a protein or a compound, thus showing that the ANO1 protein can be used as a molecular marker for the prognosis estimation and precancerous disease progression risk prediction of the esophageal squamous carcinoma.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI

Function of HOXD-AS1 in diagnosis and treatment of esophageal squamous carcinoma

The invention discloses a function of HOXD-AS1 in diagnosis and treatment of esophageal squamous carcinoma and relates to discovery, detection and application of long-chain noncoding RNA. According to the sequences of the long-chain noncoding RNA, a specific real-time quantitative PCR primer is designed and synthesized; a real-time quantitative PCR preparation is utilized to detect the expression level of the long-chain noncoding RNA in a clinical case specimen of the esophageal squamous carcinoma, and results show that the expression of the long-chain noncoding RNA in the esophageal squamous carcinoma is remarkably up-regulated and the expression level of the long-chain noncoding RNA is highly associated with both clinical stages and pathological N stages of an esophageal squamous carcinoma patient. The specific detection sequences disclosed by the invention are expected to be used for preparing the preparation for auxiliary diagnosis, curative effect prediction or prognosis judgment of the esophageal squamous carcinoma. In addition, two siRNA sequences for specifically knocking down the expression of the long-chain noncoding RNA are designed and synthesized; an experiment proves that after the expression level of the long-chain noncoding RNA is specifically knocked down in a human esophageal squamous carcinoma cell strain, the quantity of migrated tumor cells is remarkably reduced; therefore the siRNA sequences disclosed by the invention is also expected to be used as a molecular targeting treatment tool for inhibiting the cell migration rate of the esophageal squamous carcinoma.
Owner:江苏万成生物医学研究院有限公司

Application of miR-3613 as miRNA marker in distinguishing metastasis and non-metastasis of lung squamous carcinoma

The invention discloses an application of miR-3613 as a miRNA marker in distinguishing metastasis and non-metastasis of lung squamous carcinoma. Accordingly, the miR-3613 can be used for developing products for diagnosing lung squamous carcinoma metastasis and drugs for treating lung squamous carcinoma metastasis. The research result of the invention provides a theoretical basis for making individual-based treatment schemes by clinical physicians and can provide a new drug target for developing lung squamous carcinoma drugs.
Owner:QINGDAO MEDINTELL BIOMEDICAL CO LTD

Group of LncRNA biological markers for diagnosing human lung squamous carcinoma

The invention relates to the field of biotechnologies, and in particular relates to a group of LncRNA biological markers for diagnosing human lung squamous carcinoma, a related kit and applications thereof. The group of LncRNA biological markers for diagnosing the human lung squamous carcinoma, provided by the invention, comprises ENST00000453324, ENST00000441841, uc011cly.2, NR_028500 and NR_046326. The LncRNA biological markers for diagnosing the human lung squamous carcinoma can be used for distinguishing human early lung squamous carcinoma, the AUC value of the LncRNA biological markers for distinguishing the early lung squamous carcinoma and pairing normal lung tissues can reach 0.932, and the sensitivity and the specificity can be 92% and 87% respectively.
Owner:SHANGHAI INST OF MICROSYSTEM & INFORMATION TECH CHINESE ACAD OF SCI

Micro-fluidic chip used for simultaneous detection of bladder cancer cells, calculi, blood cells, and bacteria in urine

The invention belongs to the technical field of cell detection apparatus, and relates to a micro-fluidic chip used for simultaneous detection of bladder cancer cells, calculi, blood cells, and bacteria in urine. The micro-fluidic chip is composed of a lower sample channel layer and an upper pneumatic microvalve layer used for controlling on-off of sample channels; the lower sample channel layer is composed of an urine sample inlet, an urine sample main channel, and an urine sample outlet liquid storage tank; a plurality of detecting units, including an urinary calculi interception unit, an urinary bladder transitional epithelial cancer detection unit, an urinary bladder adenocarcinoma cell detection unit, an urinary bladder squamous carcinoma cell detection unit, a blood cell detection unit, and a bacterium detection unit , are arranged on the urine sample main channel; and the detecting units are connected in series, and are arranged in a circular symmetry manner. The micro-fluidic chip is high in specificity and sensitivity, can be used for determining that whether a patient suffers from bladder cancer and urinary tract symptoms just via detection on urine, and is a cheap high-efficiency urine detection tool.
Owner:锐志微创医疗科技(常州)有限公司

Application of amlodipine to preparation of medicaments for curing phoproliferative diseases

The invention relates to an application of amlodipine to the preparation of medicaments for curing phoproliferative diseases. The amlodipine is selected from racemic amlodipine, levorotatory amlodipine and pharmaceutically acceptable salts, and the phoproliferative diseases particularly refer to various malignant tumors, such as leukemia, lung cancer, gastric cancer, liver cancer, ovarian cancer, prostatic cancer, cervical cancer, breast cancer and squamous carcinoma.
Owner:CSPC ZHONGQI PHARM TECH (SHIJIAZHUANG) CO LTD

Method for diagnosing head and neck squamous cell carcinoma

Disclosed are protein biomarkers and their use in diagnosing head and neck squamous cell carcinoma (HNSCC) or to make a negative diagnosis in patients. Also disclosed are kits for the diagnosis of HNSCC that detect the protein biomarkers of the invention, as well as methods using a plurality of classifiers to make a probable diagnosis of HNSCC. In certain aspects of the invention, the methods include use of a decision tree analysis. Various computer readable media and their use according to the invention are also disclosed.
Owner:EASTERN VIRGINIA MEDICAL SCHOOL

Use of deuteroporphyrin derivates

The invention belongs to the technical field of medicament and specifically relates to use of a deuteroporphyrin derivative. The invention provides use of deuteroporphyrin derivative in preparing medicament for treating squamous carcinoma or adenocarcinoma. The treatment with the deuteroporphyrin derivative or composition and medicament thereof to squamous carcinoma or adenocarcinoma has obvious growth-inhibiting effect and good dose effect relationship. A group with high dosage has strong and stable effect and stronger inhibiting effect than the positive control medicament, hemoporphyrin. The deuteroporphyrin derivative has no growth-inhibiting effect on tumour cells under a condition of non-laser radiation, no damaging effect on normal histiocytes with light or without light and little side effect.
Owner:上海复旦张江生物医药股份有限公司

Esophageal squamous carcinoma radical postoperative patient prognosis prediction model construction method and device

The invention discloses an esophageal squamous carcinoma radical postoperative patient prognosis prediction model construction method and device, and the method comprises the steps: obtaining clinical diagnosis and treatment data and follow-up visit survival data, carrying out multi-factor Cox regression analysis on patient characteristic variables, tumor pathology characteristic variables, treatment condition variables and test index variables according to follow-up visit survival data, carrying out variable screening by utilizing a step-by-step back algorithm and an Akaike information criterion, and carrying out variable screening on the screened candidate variables again to obtain modeling variables; and performing multi-factor Cox regression analysis on modeling variables and interaction items of every two modeling variables to construct a prognosis prediction model of a patient after the esophageal squamous carcinoma radical operation, wherein the prediction variables comprise age, gender, tumor primary position, T stage, lymph node detection number, tumor size, preoperative hemoglobin level and N stage treatment mode interaction items. According to the method, the prediction accuracy can be improved, the optimal benefit group of different treatment schemes is defined, and the prognosis evaluation precision of the esophageal squamous cell carcinoma is realized.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

Application of rabdocetsin in preparing product for inhibiting proliferation of esophageal squamous carcinoma cells

The invention discloses application of rabdocetsin in preparing a product for inhibiting proliferation of esophageal squamous carcinoma cells. Proofed by experiment, the application has the advantages that the rabdocetsin can effectively inhibit the proliferation of the esophageal squamous carcinoma cells, the cloning formation of the esophageal squamous carcinoma cells, affecting the cycle progress of the esophageal squamous carcinoma cells, inducing the retardation of the cycle of the esophageal squamous carcinoma cells, inhibiting the DNA (deoxyribonucleic acid) restoration of the esophageal squamous carcinoma cells, inducing the withering of the esophageal squamous carcinoma cells, regulating up the expression amount of cleaved-caspase-9, regulating up the expression amount of cleaved-caspase-3, regulating up the expression amount of cleaved-PARP, inhibiting Akt signal pathways, inhibiting NF-kappa B signal pathways, and inhibiting the growth of tumors caused by the esophageal squamous carcinoma cells; the important application value is realized.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products